Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401530 | 1.00 | TSHR (0.47) | TSHRTDP1MEN1KMT2AAKR1B1 | |
| SCHEMBL13703082 | 0.90 | — | — | |
| SCHEMBL13703083 | 0.90 | — | — | |
| SCHEMBL15305068 | 0.83 | — | — | |
| SCHEMBL716528 | 0.83 | — | — | |
| SCHEMBL7555690 | 0.83 | — | — | |
| SCHEMBL1791605 | 0.83 | — | — | |
| SCHEMBL8024863 | 0.83 | — | — | |
| SCHEMBL8665581 | 0.83 | GAPDH (0.46) | TSHRTDP1MEN1KMT2AAKR1B1 | |
| SCHEMBL5153779 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101925554-B | Shrinkage reducing agent | CONSTR RES & TECH GMBH | 2014-06-18 | — | — | CN | disclosed |
| US-8353983-B2 | Shrinkage reducing agent | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20120266782-A9 | Shrinking Reducing Agent | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2247552-B1 | SHRINKAGE REDUCING AGENT | CONSTR RES & TECH GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-20120125236-A1 | Shrinking Reducing Agent | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| CN-101925554-A | Shrinkage reducing agent | CONSTR RES & TECH GMBH | 2010-12-22 | — | — | CN | disclosed |
| EP-2247552-A1 | SHRINKAGE REDUCING AGENT | Construction Research & Technology GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095131-A1 | SHRINKAGE REDUCING AGENT | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120125236-A1 | Shrinking Reducing Agent | BCL2A1, CCAR2, C1R | TSHR 3936/4885TDP1 2778/4885MEN1 347/4885 |
| US-20120266782-A9 | Shrinking Reducing Agent | BCL2A1, CCAR2, C1R | TSHR 3936/4885TDP1 2778/4885MEN1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.